Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Exeter, NH (Sept. 19)—Specialty pharmaceutical company Bentley Pharmaceuticals (www.bentleypharm.com) has entered into an agreement with Cardinal Health (Dublin, OH, www.cardinal.com) for the scale-up of clinical supplies for Bentley’s intranasal insulin product candidate. Under current good manufacturing practices, Cardinal’s North Raleigh (NC) facility will manufacture clinical supplies for Bentley’s “CPE-125” drug delivery technology. The companies previously collaborated at Cardinal’s Research Triangle Park (NC) facility, where the product was characterized.

The platform is designed to deliver insulin through a patient’s nasal mucosa via a small nasal spray. Bentley expects to continue its intranasal insulin program through global Phase II trials this year, according to a statement by company president John A. Sedor.

On Sept. 6, 2006, Cardinal announced it had won approval from the US Food and Drug Administration to begin production at its sterile facility in North Raleigh. Ovation Pharmaceutical’s (www.ovationpharmaceuticals.com) “Panhematin” (hemin for injection) was the first commercial drug to be manufactured at the new facility, which was built in 1997 and acquired when Cardinal bought Magellan Labs in 2001.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here